PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Clinical Trials
5.0k
Trial Phases
6 Phases
Drug Approvals
69
Drug Approvals
Rimegepant Sulfate Orally Disintegrating Tablets
- Product Name
- 乐泰可
- Approval Number
- 国药准字HJ20240004
- Approval Date
- Jan 23, 2024
Ritlecitinib Tosylate Capsules
- Product Name
- 乐复诺
- Approval Number
- 国药准字HJ20230118
- Approval Date
- Oct 18, 2023
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (3899 trials with phase data)• Click on a phase to view related trials
A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489
- First Posted Date
- 2025-07-18
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT07073820
A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe
- Conditions
- COVID-19 (Coronavirus Disease 2019)
- Interventions
- Drug: nirmatrelvir-ritonavir
- First Posted Date
- 2025-07-18
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 84584
- Registration Number
- NCT07072793
- Locations
- 🇺🇸
Pfizer New York, New York, New York, United States
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2025-07-14
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 400
- Registration Number
- NCT07062965
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
- Conditions
- Severe Alopecia Areata
- Interventions
- Drug: Ritlecitinib higher doseDrug: Ritlecitinib lower dose
- First Posted Date
- 2025-06-19
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 140
- Registration Number
- NCT07029828
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
- Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC)Hormone Sensitive Prostate CancerProstate CancerCancer of the Prostate
- Interventions
- First Posted Date
- 2025-06-19
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1000
- Registration Number
- NCT07028853
- Locations
- 🇺🇸
Arizona Urology Specialists (AUS)-Professional Park, Tucson, Arizona, United States
🇺🇸Arizona Urology Specialist, Tucson, Arizona, United States
🇨🇳Nantong Tumor Hospital, Nantong, Jiangsu, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 636
- Next
News
Roche Explores Direct-to-Consumer Drug Sales Model to Reduce US Patient Costs
Roche is considering selling prescription medicines directly to US consumers to lower patient costs, following government pressure to reduce drug prices.
RedHill Biopharma Receives FDA Approval for Groundbreaking MAP-Targeted Crohn's Disease Study
RedHill Biopharma received positive FDA feedback for the first-ever clinical study targeting Mycobacterium avium subspecies paratuberculosis (MAP) infected Crohn's disease patients with RHB-204.
Turkish Study Links Pfizer COVID-19 Vaccine to Corneal Structural Changes
A Turkish study of 64 patients found measurable corneal changes 75 days after receiving two doses of the Pfizer-BioNTech COVID-19 vaccine, including 2% increased thickness and 8% reduced endothelial cell density.
BioNTech Chief Strategy Officer Ryan Richardson to Step Down After Seven-Year Tenure
Ryan Richardson will step down as Chief Strategy Officer from BioNTech's Management Board on September 30, 2025, after serving since January 2020.
Bristol Myers Squibb and Pfizer Launch Direct-to-Patient Eliquis Program with 40% Price Discount
Bristol Myers Squibb and Pfizer announced a new direct-to-patient purchasing option for Eliquis (apixaban) through their Eliquis 360 Support program, offering eligible patients a cash price more than 40% below the current $606 list price.
Sarepta Therapeutics Implements $400 Million Cost-Cutting Plan Amid Regulatory Challenges for Gene Therapy
Sarepta Therapeutics announced a $400 million annual cost-savings initiative in July 2025, including a 36% workforce reduction of 500 employees to achieve financial sustainability through 2027.
Iovance Biotherapeutics Names Corleen Roche as CFO During Commercial Launch of First FDA-Approved TIL Therapy
Iovance Biotherapeutics appointed Corleen Roche as Chief Financial Officer effective August 6, 2025, during the commercial launch of its groundbreaking TIL therapy.
Oxford BioDynamics' EpiSwitch Biomarkers Show Promise in Pfizer Bladder Cancer Trial
Oxford BioDynamics' EpiSwitch blood-based biomarkers demonstrated strong correlation with immune profiles of patient tumors in Pfizer's JAVELIN Bladder 100 trial involving 496 bladder cancer patients.
Uniquity Bio Appoints Will Kane as CEO to Lead Anti-TSLP Therapy Through Phase III Development
Uniquity Bio has appointed Will Kane as President and CEO to advance solrikitug, a monoclonal antibody targeting TSLP, through completion of three Phase II trials and preparation for Phase III development.
ViiV Healthcare Expands Generic License for Long-Acting HIV Treatment to 133 Countries
ViiV Healthcare has expanded its voluntary licensing agreement with the Medicines Patent Pool to allow generic production of cabotegravir for HIV treatment in 133 countries, including all low-income and Sub-Saharan African nations.